David A. Sinclair, A.O., Ph.D. is Professor of Genetics at Harvard Medical School and serves as president of the non-profit Academy for Health & Lifespan Research. At Harvard Medical School, Professor Sinclair heads a leading research lab that has discovered why we age and how to control it. He is the inventor on more than 50 patents and has published over 180 papers that have been cited over 83,000 times. Professor Sinclair is a serial entrepreneur who has co-founded over a dozen successful companies including MetroBiotech, EdenRoc Sciences, Tally Health, and Life Biosciences. Professor Sinclair is a leading world authority on aging and longevity, and has been recognized as one of TIME magazine’s 100 Most Influential People In The World for his scientific research and Information Theory of Aging. Professor Sinclair is the New York Times bestselling author of Lifespan: Why We Age-And Why We Don’t Have To and host of the Lifespan podcast, which has peaked as the #1 Health & Fitness show on Apple Podcasts. Professor Sinclair and his work have been featured in media publications including Fortune, The Wall Street Journal, and The New York Times. He has received more than 40 awards for his research and scientific breakthroughs, including Innovator of the Year, the National Institutes of Health’s Pioneer Award, and appointment as an Officer of the Order of Australia for his work in scientific communication and national security. Professor Sinclair holds board seats on for-profit and non-profit organizations, and co-founded the scientific journal Aging as well as Fully Aligned Co, which works to democratize access to knowledge and tools to enhance mind and body wellbeing.

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation generative artificial intelligence technologies for drug discovery and biomarker development. Under his leadership, Insilico raised over $400 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 11 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. Since 2015 he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. Since 2012 he published over 160 peer-reviewed research papers and 2 books. He founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (10th annual in 2023), the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Dr. Nir Barzilai serves as director of the Institute for Aging Research at the Albert Einstein College of Medicine. In addition, he is a founder and board member of CohBar Inc. Listed on the Russel 2000 Index, it develops therapeutics based on mitochondrial-derived peptides. He is a renowned expert and scientist in the study of the biology and genetics of aging. He is also a founder and a Medical Consultant to Lifebiosciences, targeting therapeutics against the hallmark of aging. He is leading the TAME (Targeting Aging with MEtformin) multi-central study to show that aging can be a target in humans in support of changing the FDA indication that is relevant to targeting aging. Dr. Barzilai is the recipient of many awards including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity Award. His work has been profiled by outlets such as the New York Times, BBC, PBS, and National Geographic. He received his MD from Technion-Israel Institute of Technology.

Dr. Eric Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Ageing. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Gladstone Institute at the University of California San Francisco (UCSF). Dr. Verdin is currently adjunct Professor of Medicine at UCSF and Adjunct Professor at the University of Southern California (USC).​

Bryan Johnson is the world's most measured human. Johnson sold his company, Braintree Venmo, to PayPal for $800m in 2013. Through his Project Blueprint, Johnson has achieved metabolic health equal to the top 1.5% of 18 year olds, inflammation 66% lower than the average 10 year old, and reduced his speed of aging by the equivalent of 31 years. Johnson freely shares his protocols and data publicly for everyone to use. Project Blueprint, is an endeavor to achieve humanity and earth scale cooperation starting within Self. In 2023, Johnson launched Rejuvenation Olympics, a leaderboard assessing one's speed of aging using DNA methylation. Of the 1,750 people who have been using this state-of-the-art aging algorithm to track their progress longitudinally, Johnson ranks #1 in speed of age reduction. Johnson is also the founder & CEO of Kernel, creator of the world’s first mainstream non-invasive neuroimaging system; and OS Fund, where he invested $100M in the predictable engineering of atoms, molecules, and organisms into companies now collectively valued over $6B. He is an outdoor adventure enthusiast, pilot, and author of children’s books, Code 7 and The Proto Project.

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Program, and (3) the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality.

Dr Andrew Steele is a scientist and author of Ageless: The new science of getting older without getting old. After a PhD in physics from the University of Oxford, Andrew decided that ageing was the single most important scientific challenge of our time, and switched fields to computational biology. After five years using machine learning to investigate DNA and NHS medical records, he is now a full-time writer, presenter and campaigner. He has appeared on Discovery and the BBC, produces his own videos on YouTube and gives live talks ranging from lectures to science stand-up at the Hammersmith Apollo.

Michael Greve is the founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures. With his own team, he produces scientific papers that can be thought of as a screenshot of current world knowledge on a topic - each paper based on about 2000 abstracts and 150 studies. He publishes them in a database on his website, freely accessible to anyone at any time, comprehensively transformed into practical advice. He has turned himself into the leading global figure of a new approach to longevity: he talks about rejuvenation, the preservation and restoration of youth. He talks about viewing the process of aging as a treatable disease, not an inescapable fate. All this not with the goal of eternal life, but of prolonging the healthy life span as much as possible.

Dr Greg Bailey is the cofounder, executive chairman and former CEO of Juvenescence, a biopharma developing therapeutics to modify diseases of ageing. Juvenescence has aggregated an ecosystem of some of the top scientists and drug developers to create therapeutics to prevent aging and increase healthspan. The range of therapeutics varies from conventional pharmaceuticals, natural products and the regeneration of tissue and organs. Dr. Bailey is a serial entrepreneur, founder and financier of biotech companies since 1995. His companies have been traded on NASDAQ, AIM, AMEX and the NYSE, reaching over $28 billion in market capitalization. They include Ascent Health Care, which was sold to Stryker for $525 million, Medivation Inc., (MDVN: NASDAQ) which was acquired by Pfizer in September 2016 for $14.3 billion and Biohaven (BHVN:NYSE) which sold one of its drugs for $11.8 billion to Pfizer. Dr. Bailey continues to be on the board of directors of Biohaven. He has a medical doctorate from University of Western Ontario.

David Gobel heads the Methuselah Foundation, a medical charity that was organized in 2000 and is based in Springfield, Virginia. Under Gobel's leadership, Methuselah has invested millions of dollars to support research and development in regenerative medicine, regenerative medicine, and is actively involved in efforts to change how the public thinks about extending the healthy human lifespan. Gobel established Methuselah in order to, as stated on its original website, "shed light on the processes of aging and find ways to extend healthy life." The organization works in a variety of ways: Incubating companies that are developing breakthrough technologies, supporting mission-relevant ventures that promote longevity research, funding such research directly and supporting projects and prizes to accelerate breakthroughs in longevity. Since 2014, the Methuselah Foundation has a self-imposed deadline to “make 90 the new 50 by 2030.”

Dr. Aubrey de Grey is a biomedical gerontologist based in Silicon Valley, California, USA, and is the founder, President, and Chief Science Officer of LEV Foundation, a biomedical research and advocacy charity focused on repairing the molecular and cellular damage of aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterization of all the types of damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association and sits on the editorial and scientific advisory boards of numerous journals and organizations. He is a highly sought-after speaker who gives frequent invited talks at scientific conferences, universities, and companies in areas ranging from pharma to life insurance, and to the public.

Prof. Evelyne Bischof is a Chief Physician Associate of Internal Medicine at University Hospital Renji of Jiaotong University Shanghai and concierge longevity physician for executive longevity patients. Her research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. She published over 80 peer-reviewed papers, is a frequent speaker at scientific and medical conferences in Asia and Europe. Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc. Evelyne spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice.

Jörg is a serial investor and entrepreneur who started his first company right after college. After only 3 years he successfully excited his first company and since then he is passionate about building companies that make an impact. Jörg established, amongst other companies, a leading European IT asset management strategy consultancy which he sold to one of the BIG4 where he then served 4 more years as global lead partner. Jörg has so far invested in more than 25 start-ups as well as midsized companies. With 9 out of 10 start-ups successful (including 2 IPOs and 1 Unicorn) Joerg has shown a good hand in building and investing in companies. He is a member of selected Advisory Boards and teaches “Entrepreneurship and Innovation” at a leading private university in Germany.

Alexandra is a Co-Founder and Investment Director at Apollo Health Ventures, a leading venture capital fund focused on biomedical innovations to enhance human health and longevity. As a trained pharmacist and biomedical science PhD, Alexandra followed her passion for improving healthy longevity. During her PhD studies at Harvard Medical School, she focused on investigating the molecular mechanisms that contribute to cellular aging and may be targeted to increase mammalian health span. After her PhD, Alexandra worked with The Boston Consulting Group where she specialized on biopharma strategy to drive the development and commercialization of innovative therapeutics. At Apollo, Alexandra is leading the venture creation programs, conceptualizing innovative biotech ventures that target the aging process at the molecular level.

Prof. Dr. Collin Y. Ewald has a longstanding interest in the molecular biology of healthy aging and age-related pathologies (https://en.wikipedia.org/wiki/Collin_Y._Ewald). He has over 20 years of experience in gaining mechanistic insights, drug discovery, and strategies for promoting healthy longevity (www.ewaldlab.com). He is the founder and president of the Swiss Society for Aging Research (www.ssfar.ch) and vice-president of the German Society for Aging Research (https://www.alternsforschung.org/ueber-uns/vorstand). He has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences. Prof. Ewald is named one of the top 1000 Longevity Leaders worldwide and is one of Switzerland's top 15 Longevity Influencers.

Amy Killen is a leading regenerative physician focusing on sexual optimization as a driver for health and longevity. In her Utah-based practices, she combines stem cell injections with photobiomodulation, shockwave therapy, body-identical hormones, nutritional supplements, peptides, and an old-fashioned healthy lifestyle to give patients unparalleled synergistic regenerative effects for skin and sexual systems. Dr. Killen is also the founder and CEO of the Human Optimization Project, a longevity-focused nutritional supplement and education platform, and she is on the core team of Reputable, a decentralized science platform that incentivizes betterment experiments and aggregates N of 1 data into actionable insights. She practiced emergency medicine for ten years before transitioning to longevity and regenerative medicine. She now divides her time between clinical work, international speaking engagements, educational content creation, her entrepreneurial endeavors, and her family of five.

Elizabeth Parrish, the Founder and CEO of BioViva, is a humanitarian, entrepreneur, innovator, author, podcaster, and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of regenerative medicine modalities, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach. Dedicated to the cause of improving and safeguarding more and more lives, Elizabeth asserts, “We are focused on saving as many lives as possible by making tomorrow’s therapies available today."

Dr. Antoinette Sarasin Gianduzzo is the Director of our acclaimed Biomolecular Restoration Nutrition & Lifestyle Department. She is a member of the Board of Directors and founder of the BIO-R® Method. She leads an interdisciplinary team of specialists and personally oversees each client’s individual treatment plan from the initial in-depth and state of the art laboratory testing phase to the composition of tailored micronutrients and complementary, innovative treatments to correct the identified biochemical and neuro-chemical imbalances, metabolic stress factors and deficiencies resulting in a prescription as unique as a client’s fingerprint. At The Kusnacht Practice, BIO-R® is an essential component of every client’s programme; hence Dr. Antoinette works closely with the Medical Director and Psychiatric team in a joint effort to augment each client’s sense of well-being, restore vitality and achieve a higher level of mental strength and physical health. Additionally, Dr. Antoinette and her expert team provide in-person coaching to clients and instruct the practice’s personal chefs, trainers and complementary therapists, which rounds off the tailor-made holistic BIO-R® programme. Dr. Antoinette joined the Kusnacht Practice in 2010 after having built her own reputable business as an expert in nutrition and health. She was scouted by the founder of The Kusnacht Practice for her unique expertise and success and has remained with the company since. Dr. Antoinette completed her postgraduate studies in Human Nutrition at the renowned Swiss Federal Institute of Technology (ETH) with distinction and obtained her doctoral degree at the University of Zurich’s Institute of pharmacology and toxicology. She gained extensive knowledge as product manager in the pharma industry in a company specializing in prescription medication to treat nutrition-related diseases such as diabetes, obesity and cardiovascular diseases. Dr. Antoinette constantly engages in continued education and expert training to deliver innovative expertise in nutritional medicine, health and lifestyle coaching, illness prevention and rejuvenation/age reversing interventions, sustainable weight- and resource management. Presently Dr. Antoinette is designing the blueprint for a transformational treatment protocol that focuses on incorporating science backed pioneering therapies to promote longevity and stimulate reverse-aging processes in a BIO-R® context. Dr. Antoinette is an experienced keynote speaker at both, conferences and corporate events. Her work has been published in multiple magazines and her expert opinion on nutritional and healthy lifestyle issues has been broadcast on TV. She is a member of the Swiss Society for Anti-Aging Medicine and Prevention and the Swiss Society for Nutrition. Dr. Antoinette speaks Swiss German, German and French at a native speaker level, is fluent in English and Italian, and speaks some Spanish.

Felicia von Reden is the co-founder and CEO of Ovom Care, a pioneering venture reshaping reproductive healthcare by integrating data-driven AI decision-making into modern fertility clinics, elevating success rates and financial accessibility for patients. With a background in business administration, entrepreneurship, and a personal journey marked by an endometriosis diagnosis, Felicia's dedication to healthcare innovation led her from strategic consulting with IQVIA to creating veterinary clinics merged with advanced software systems. Today, driven by her passion and first-hand experience, she's focused on building the future of reproductive care she wished for herself, making her a transformative leader in the field.

Dr. Emil Kendziorra is a founder and CEO at Tomorrow Bio and President of the Board at the European Biostasis Foundation, a non-profit research foundation and institute in Switzerland. He has been leading multiple tech and medical companies, most recently as Founder and CEO of Medlanes (Exit to ZAVA) and onFeedback (Exit to QuestionPro). Prior to his career in entrepreneurship, Emil graduated summa cum laude in medicine from University Medical Center Göttingen - one of the leading medical schools in Germany - with a doctoral degree in translational cancer research. He’s a regular keynote speaker on future of healthcare, the overlap of healthcare, science and technology as well as a mentor to tech startups and an early stage angel investor. Emil has decided to dedicate the next decades of this life to Medical Biostasis and cryomedicine.

Elisabeth Roider is Harvard-and Swiss-trained, internationally renowned physician scientist. As a Partner & Chief Scientific and Medical Officer at Maximon she is dedicated to bring the field of longevity to the next level. As a physician-scientist, she is working at the University Hospital of Basel and the Harvard Medical School. Her multidisciplinary team includes clinicians and clinical trial specialists, biologists, chemists, machine learning specialists, mathematicians, statisticians, and epidemiologists, allowing a bench-to-bedside approach to solve complex, medical questions in the most efficient way. Her work has resulted in various high-impact publications, patents and awards. Driven by the mission to identify and solve the most relevant medical and public health problems, Elisabeth most recently joined Maximon as a Partner & Chief Scientific and Medical Officer. Here she aims to support scientists and physicians in transforming true innovation into solid solutions and products, helping patients and consumers to achieve a better, healthier and finally longer life.